Supplementary Figure 5. Extended data related to Figure 5.

A, Transcriptional heatmap depicting relative z-score normalized mRNA levels of the indicated target gene in LOVO cells transfected with siRNAs against a control sequence or the respective indicated target gene after treatment with vehicle or a combination of EZH2i and MEKi. Heatmap rows represent mRNA levels obtained from qRT-PCR using primers against the respective target gene between combo treated cells transfected with siCTRL and siRNA against the respective target gene. % Knockdown represents the percent decrease of the mRNA levels of the respective target gene between combo treated cells transfected with siCTRL and siRNA against the respective target gene.

B, Immunoblot with lysates from LOVO cells transduced with two different sgRNA sequences against TLE4 and treated with EZH2/MEKi. Immunoblot confirms knockdown of TLE4 with loss of protein levels after sgRNA transduction.

C, Quantifications of TLE4 protein levels from immunoblot shown in Fig. 5D. D, percentage of caspase 3/7+ LOVO siCTRL and sgTLE4 cells after treatment with the indicated agents over time as measured by Incucyte live cell imaging. P value determined with two-way ANOVA between sgCTRL and sgTLE4 combo treated cells.

E, Immunoblot with LOVO protein lysates after treatment with vehicle or MEKi after the indicated timepoints. Immunoblots demonstrate levels of pERK recover after 32-40 hours of MEKi treatment.

F, Immunoblot with LOVO protein lysates transduced with sgRNAs against a control sequence or TLE4, and then treated with vehicle, EZH2i, and/or MEKi after the indicated time points. Immunoblots reveal that knockdown of TLE4 does not affect levels of pERK.